Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialResearch in context

• Main Authors: Fuxiang Wang (Author), Wen Xiao (Author), Yimin Tang (Author), Mengli Cao (Author), Dan Shu (Author), Tetsuya Asakawa (Author), Yechun Xu (Author), Xiangrui Jiang (Author), Leike Zhang (Author), Wei Wang (Author), Jianxing Tang (Author), Yuansheng Huang (Author), Yang Yang (Author), Yumei Yang (Author), Renhong Tang (Author), Jingshan Shen (Author), Hongzhou Lu (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19. Methods: This...